Quarterly market debut research · Q3 2026
IPO Market Debuts: Q3 2026
14 selected NYSE and Nasdaq IPO debuts verified as already trading in July–September 2026, including 12 operating-company IPOs and two clearly labeled SPACs.
14 companies · 14 trading · 0 scheduled
As of
-
1. ADARx Pharmaceuticals, Inc. (ADRX · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what ADARx Pharmaceuticals, Inc. does
What they do, in plain English
ADARx is developing medicines that try to treat disease by reducing the amount of a particular protein the body makes. It uses short pieces of genetic material to turn down the instructions for making that protein, with experimental programs spanning kidney and blood disorders, swelling attacks and other conditions.
Who it's for
The intended beneficiaries are patients with diseases in its pipeline, but people who receive candidates in trials are research participants, not product buyers. As of the company’s September 2026 SEC filing, no candidate was approved for commercial sale.
How it operates
ADARx funds drug discovery, clinical testing and outsourced manufacturing, and seeks to advance candidates toward approval. Potential future income could come from selling an approved medicine itself or through partners and licenses; it has an AbbVie collaboration and license-option arrangement, but this is not a current marketed-drug business.
What to understand
The company described three clinical-stage and two advanced preclinical programs in its September 2026 filing, but said it had no product approved for sale and had not completed a clinical program. All candidates are experimental; trial results and regulatory approval are uncertain.
Business overview sources
Issuer IR confirms an all-primary IPO and identifies Nasdaq/ticker; Reuters reported shares opened and rose on Friday, September 25, confirming the actual Nasdaq debut.
Sources
-
2. Live Oak Acquisition Corp. VI (LOVIU · Nasdaq)
Actual first trade: · Status: Trading · Offering type: SPAC / blank-check IPO
Explore what Live Oak Acquisition Corp. VI does
What they do, in plain English
Live Oak Acquisition Corp. VI is a special purpose acquisition company (SPAC), or “blank-check” company: it raises public-investor money to find and buy or merge with an existing business, helping that business become publicly traded. Its August 2026 prospectus said it had not selected a target and could pursue any industry, sector or geography, so it had no operating product business at that time.
Who it's for
It has no current product or service users and no operating-company customers; people buying its IPO units are investors providing capital, not customers. Any future operating business and its customers would depend on the target it eventually acquires or combines with.
How it operates
At the IPO, proceeds were placed in a trust account for a future business combination. The SPAC intends to use that pool of capital to acquire or combine with one or more businesses; it does not earn money by selling a current product or service, and completing a transaction is not guaranteed.
What to understand
This is a SPAC, not an operating company. Its August 24, 2026 prospectus stated that no target had been selected and that no substantive target discussions had begun; it named no target sector.
Business overview sources
SPAC (blank-check company), not an operating company. Its IPO closing announcement explicitly states that units began trading on Nasdaq September 23; the ticker is for the units.
Sources
-
3. Electra Therapeutics, Inc. (ETRA · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Electra Therapeutics, Inc. does
What they do, in plain English
Electra is developing antibody medicines designed to remove selected immune cells thought to drive serious diseases. Its lead experimental medicine is being studied for a dangerous overreaction of the immune system and certain blood cancers; another candidate is being tested for diseases involving T cells, a type of immune cell.
Who it's for
The intended beneficiaries are patients with sHLH, certain blood cancers and other immune-mediated diseases; healthy volunteers in the ELA822 Phase 1 study are trial participants, not customers. The company’s SEC prospectus said it had no products approved for sale and had never generated revenue.
How it operates
Electra spends capital on antibody research, clinical trials and development, and plans to build a focused commercial organization around its lead candidate if development and approval succeed. It also intends to explore strategic collaborations; potential product revenue depends on successful trials, regulatory approval and later commercialization.
What to understand
Electra is a clinical-stage biopharmaceutical company, not a seller of approved medicines. Ipsoprubart and ELA822 were investigational candidates as of the October 1, 2026 cutoff, so their potential benefits are unproven and approval is not assured.
Business overview sources
Issuer IR confirms IPO pricing and Nasdaq ticker; HBM Healthcare Investments' post-IPO release explicitly states that Electra shares began trading September 18.
Sources
-
4. Lyntris Inc. (LYNX · NYSE)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Lyntris Inc. does
What they do, in plain English
Lyntris supplies military customers with integrated sensors, radio hardware and software that collect, combine and display field data so users can move from detection to operational decisions—the company’s “sense-to-act” description. Its systems support maritime surveillance, air and missile defense, and space surveillance and resilient communications across military domains.
Who it's for
Its customers are U.S. Department of Defense and allied-country military organizations and programs, rather than consumers. The prospectus said the company supported more than 200 U.S. and allied defense programs during 2025.
How it operates
Lyntris designs and supplies proprietary sensor subsystems, antennas and software, and integrates them into defense programs through customer contracts. It also describes a strategy of acquiring and combining complementary defense-technology businesses to broaden its capabilities.
What to understand
Lyntris is a holding company formed in May 2026 by combining two existing businesses, Accelint and Vitesse, and holds the equity of operating subsidiaries. It is an operating defense-technology supplier, not a precommercial biotech or a blank-check company.
Business overview sources
The SEC-filed pricing announcement shows an IPO with issuer primary shares plus selling-stockholder shares and an expected August 19 NYSE start; Reuters reported the shares' actual New York debut on August 19.
Sources
-
5. Londian Wason New Energy Tech Inc. (FOIL · NYSE)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Londian Wason New Energy Tech Inc. does
What they do, in plain English
Londian Wason manufactures electrolytic copper foil: very thin conductive copper used in lithium-ion batteries and printed circuit boards (the boards that connect electronic components). It also makes flexible copper-clad laminate, a copper-and-insulating-material base used to build circuits.
Who it's for
Its direct buyers are battery and electronic-circuit manufacturers, including companies named in its prospectus such as LG Energy Solution, Panasonic Industrial Materials, SK On, Samsung SDI, CATL and BYD. Drivers of electric vehicles and users of electronics are downstream users, not the company’s direct customers.
How it operates
The company researches, manufactures and sells copper foil and related laminate products to industrial manufacturers. Its product specifications serve different battery and circuit-board applications; the prospectus describes production and customer relationships rather than a consumer-facing business.
What to understand
The listed issuer is a Cayman Islands holding company, while it conducts most operating activity through subsidiaries in China, according to its SEC prospectus. This describes an established materials manufacturer, not an early-stage product-development company.
Business overview sources
The company's official-listing announcement dated August 13 states that it completed its NYSE listing that day and describes that date as the debut trading day. This uses the actual official listing/debut, not the earlier anticipated date in its pricing announcement.
Sources
-
6. Vogenx, Inc. (VOGX · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Vogenx, Inc. does
What they do, in plain English
Vogenx is developing medicines for digestive and metabolic conditions. Its lead experimental pill is designed to slow the movement of sugar from the intestine into the bloodstream, and is being studied for low blood sugar after weight-loss surgery and for abnormally slow stomach emptying.
Who it's for
The intended beneficiaries are patients with post-bariatric hypoglycemia and gastroparesis, not current commercial buyers. Any people receiving mizagliflozin in a study are trial participants; the SEC filing said Vogenx had no product approved for sale and had never generated product-sales revenue.
How it operates
Vogenx licensed rights to mizagliflozin from Kissei Pharmaceutical (excluding Japan, South Korea and Taiwan) and is investing in its development and testing. It could generate product-sales revenue only if it completes development and obtains approval, either by commercializing itself or with collaborators; its SEC filing says it had not yet established commercial-scale manufacturing or sales and marketing capabilities.
What to understand
Vogenx is clinical-stage, and mizagliflozin remains investigational rather than an approved treatment. Its July 2026 prospectus said its development had not advanced beyond Phase 2 and that it had no product approved for sale.
Business overview sources
The issuer's closing announcement explicitly says its common stock began trading on the Nasdaq Capital Market August 12.
Sources
-
7. Braveheart Bio, Inc. (BRVE · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Braveheart Bio, Inc. does
What they do, in plain English
Braveheart is developing a pill for a condition in which the heart muscle becomes abnormally thick, sometimes restricting blood leaving the heart. Its experimental medicine aims to moderate the protein that drives heart-muscle contraction, and it is being studied in patients both with and without that obstruction.
Who it's for
The intended beneficiaries are people with obstructive or non-obstructive HCM, but clinical-trial participants are not commercial customers. BHB-1893 was investigational and not an approved treatment as of the cutoff date.
How it operates
Braveheart is developing BHB-1893 under an exclusive license from Jiangsu Hengrui Pharmaceuticals and is spending on clinical studies and development. Any commercial revenue depends on approval and later sales, either by Braveheart or a third party; its prospectus said it had not yet established commercial-scale manufacturing or sales and marketing activities.
What to understand
This is a clinical-stage drug developer, not a company selling an approved therapy. A Phase 3 trial (a large confirmatory study) for obstructive HCM was initiated by September 8, 2026; that milestone does not mean the drug is proven or approved.
Business overview sources
The issuer's closing announcement explicitly says the IPO shares began trading on Nasdaq August 6.
Sources
-
8. TCGX Acquisition Corp. (TCGX · Nasdaq)
Actual first trade: · Status: Trading · Offering type: SPAC / blank-check IPO
Explore what TCGX Acquisition Corp. does
What they do, in plain English
TCGX Acquisition is a special-purpose company created to combine with or buy another business, rather than a company selling a product today. Its prospectus says it plans to look especially at healthcare, life sciences and medical technology, although it may pursue a target in any sector.
Who it's for
It has no operating product or ordinary product customers; its immediate constituency is its public shareholders, while any future operating customers would belong to the company it acquires.
How it operates
It raises money by selling shares in an IPO and holds the proceeds in a trust while it searches for a business to merge with or acquire. A completed deal would make it part of a combined operating company; the prospectus provides for redeeming public shares if no deal is completed within its stated period.
What to understand
As of the IPO prospectus, TCGX had selected no target and had generated no operating revenue. The healthcare/life-sciences/medtech focus is a stated search preference, not a committed target or an existing business line.
Business overview sources
SPAC (blank-check company), not an operating company. Its closing announcement states that its Class A ordinary shares began trading on Nasdaq August 5.
Sources
-
9. Apnimed, Inc. (APMD · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Apnimed, Inc. does
What they do, in plain English
Apnimed develops oral medicines for sleep-related breathing disorders. Its main candidate, AD109 (also called Oxnimbi in its filings), is a once-nightly pill being studied for obstructive sleep apnea, in which the airway repeatedly narrows or closes during sleep.
Who it's for
The intended patients are adults with obstructive sleep apnea; physicians and healthcare payers are among the groups that would influence prescribing and access. There are no commercial users of the medicine while it remains unapproved.
How it operates
Apnimed discovers and develops drug candidates and intends to commercialize prescription medicines if regulators approve them. Its planned commercial business therefore depends on getting a product approved and used; its lead candidate had not yet reached that point by the research cutoff.
What to understand
As of October 1, 2026, AD109 was Apnimed's sole clinical-stage candidate; it had completed two Phase 3 trials and its U.S. application was under FDA review. It remained an investigational medicine, not an available treatment.
Business overview sources
The issuer's closing announcement explicitly states that its common stock began trading on Nasdaq July 31.
Sources
-
10. Scribe Therapeutics Inc. (SCTX · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Scribe Therapeutics Inc. does
What they do, in plain English
Scribe Therapeutics engineers CRISPR-based medicines—using a molecular tool to control genetic instructions—with an initial focus on heart and metabolic diseases. Its lead candidate is designed to reduce LDL, often called “bad” cholesterol, by turning down a gene's activity without permanently changing the DNA sequence.
Who it's for
The intended patients include people with elevated LDL cholesterol and other cardiometabolic risks; drug-company partners can also use Scribe's technology in collaborative research programs. Scribe had no approved patient-facing product at the cutoff.
How it operates
Scribe develops its own medicine candidates and works with pharmaceutical partners on other programs. Its filings describe collaboration income from upfront payments, research funding, development milestones and potential royalties, alongside grants; it had not generated product revenue by the IPO filing.
What to understand
At the October 1, 2026 cutoff, lead candidate STX-1150 had entered a first-in-human clinical trial, but remained experimental. The company's other medicines were also in development, not approved products.
Business overview sources
The issuer's closing announcement explicitly states that its common stock began trading on Nasdaq July 24.
Sources
-
11. Standard Nuclear, Inc. (STDN · NYSE)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Standard Nuclear, Inc. does
What they do, in plain English
Standard Nuclear designs and manufactures TRISO fuel, a nuclear-fuel design made from tiny uranium-based particles with protective coatings, for certain advanced reactor designs. It makes fuel rather than designing, owning or operating the reactors themselves.
Who it's for
Potential customers include advanced-reactor developers and the utilities, reactor operators, data-center operators and government entities that use TRISO-fueled reactors. Customers generally supply the enriched uranium feedstock that Standard Nuclear processes.
How it operates
The company plans to supply finished fuel under long-term contracts: customers provide enriched uranium, and Standard Nuclear converts it into fuel, generally pricing the product by the amount of uranium and adjusting for enrichment and fuel specifications.
What to understand
Its IPO prospectus says it had not yet sold fuel at large-scale commercial levels and that the economics of industrial-scale TRISO production were not yet fully established. It is a fuel supplier, not a reactor operator, and the uranium feedstock is generally procured by its customers.
Business overview sources
The issuer's pricing announcement identified the NYSE ticker and expected date; Reuters reported the shares' NYSE debut and opening on July 16, confirming the actual first trade day. The NYSE later described its bell ceremony as following the trading debut.
Sources
-
12. Bending Spoons S.p.A. (BSP · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Bending Spoons S.p.A. does
What they do, in plain English
Bending Spoons buys and operates a portfolio of digital products, rather than selling just one app. For example, Airtable helps teams organize information and workflows, while Eventbrite lets organizers sell event tickets and helps attendees discover events and buy tickets.
Who it's for
Customers vary by product and include individuals and organizations that subscribe to software or other digital services, as well as advertisers, event creators and ticket buyers for products that offer those services.
How it operates
It acquires digital businesses, operates and updates them, and reinvests in further acquisitions. Its 2026 financial statements identify subscriptions, advertising and other service fees—including ticketing and payment processing in some businesses—as revenue sources.
What to understand
Bending Spoons is a portfolio operator, so users, services and revenue sources differ across the businesses it owns. The cited subscription, advertising and transaction-fee mix describes its disclosed portfolio model, not one uniform product.
Business overview sources
The issuer's IPO closing announcement explicitly says its ordinary shares began trading on Nasdaq July 1. The IPO included both issuer shares and selling-shareholder shares.
Sources
-
13. ITG, Inc. (ITG · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what ITG, Inc. does
What they do, in plain English
ITG, Inc. provides field and technical services for building, upgrading and maintaining communications and other utility infrastructure in the United States. Its work can cover a network's life cycle, from planning and installation to ongoing repairs and maintenance.
Who it's for
Its contracting customers include broadband and fiber providers, wireless carriers, data-center operators, and public and private utilities; the networks and infrastructure they operate are used by businesses and the public.
How it operates
ITG sells engineering, construction, installation, maintenance and related services, typically through multi-year service agreements as well as larger infrastructure-deployment projects. Repeat maintenance work can continue after a network is built.
What to understand
The listed holding company sits above ITG Communications LLC and its subsidiaries, which carry out the operating business. Its role is to build and maintain infrastructure for contracting customers, rather than to manufacture the phones or computers people use to connect to those networks.
Business overview sources
The issuer's completed-IPO announcement explicitly states that its Class A common stock began trading on Nasdaq July 1.
Sources
-
14. Neutron Holdings, Inc. (Lime) (LIME · Nasdaq)
Actual first trade: · Status: Trading · Offering type: Operating-company IPO
Explore what Neutron Holdings, Inc. (Lime) does
What they do, in plain English
Lime, operated by Neutron Holdings, rents app-unlocked electric scooters and bicycles for short trips in cities. Its service combines a shared vehicle fleet, a rider app and local operating arrangements with cities.
Who it's for
Riders are the direct users and pay for rides; cities and municipalities are important deployment and permitting partners, rather than necessarily the direct payer for each trip.
How it operates
Lime earns per-ride unlock fees and per-minute charges, and also sells bundles of ride minutes and recurring subscriptions with ride benefits. It deploys, charges, retrieves and maintains its own shared fleet.
What to understand
Operating permissions are set city by city, so permits and local rules are a structural part of the business. The fleet also requires continuing maintenance, replacement and other vehicle costs.
Business overview sources
Issuer IR described a primary IPO with a small selling-stockholder component and said trading was expected July 1; Reuters reported Lime's Nasdaq debut on July 1, confirming actual trading rather than relying on pricing date.
Sources
Methodology
Discovery used exchange IPO information and reputable IPO pricing/calendar histories (including NYSE IPO Data and IPOScoop) for candidate generation only. Every included row was then checked against fetched source content: issuer IR or issuer-distributed IPO closing/listing announcements, an SEC-filed pricing exhibit where available, and/or reporting on the actual debut. FirstTradeDate records the date trading actually commenced or the reported market debut, never the offer/pricing date by itself. Screened out direct listings, uplistings/exchange transfers, business-combination listings, secondary-only/resale offerings, announced-but-not-traded candidates, and entries for which the actual debut could not be verified. SPACs are included only as SPACs, not as operating companies. Entries are shown newest first.
Coverage
Selected evidence-backed coverage: 14 verified entries (6 July, 5 August, 3 September), including two SPACs. This is not asserted to be a complete census of all Q3 U.S. IPOs; coverage was limited to candidates for which the actual first-trade/debut evidence and issuer/ticker/exchange could be verified. Calendar discoveries and expected IPOs are not treated as completed listings.
Important note
Informational research only, not investment, legal or financial advice. This selected report is not a complete census or a live quote service. Exchange listing does not imply membership in a stock index. SPACs are blank-check acquisition companies, not operating businesses.